This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
by Ekta Bagri
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
biotechnology biotechs dividend-yield medical pharmaceuticals
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.
biotechs
Can Amgen's MariTide Take on Leaders in the Obesity Space?
by Zacks Equity Research
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
biotechs medical pharmaceuticals
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
by Sundeep Ganoria
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
biotechnology biotechs cell-therapy medical pharmaceuticals vaccines
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
by Zacks Equity Research
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
biotechs
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
by Sundeep Ganoria
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
biotechs medical
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
by Zacks Equity Research
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
biotechs
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
by Zacks Equity Research
MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
biotechs
3 Biotech Stocks With Major 2026 Catalysts
by Ekta Bagri
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
biotechnology biotechs medical pharmaceuticals
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
by Kanishka Das
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
biotechs